When playing the NK cell therapy card in glioblastoma, you can't beat interleukin-21.

Glioblastoma is the most common brain cancer, with a 5-year survival rate of less than 10%. This grim prognosis highlights the urgent need for novel therapeutic approaches. In this issue of Cancer Cell, Shanley et al. ¹ report an innovative engineering strategy to supercharge NK cell immunity against glioblastoma.
Competing Interests: Declaration of interests N.D.H. reports stock or other ownership in oNKo-Innate and serves on advisory boards for Bristol Myers Squibb and Syena. N.D.H. is an inventor on multiple patents related to using adoptive NK cell therapy for cancer and targeting IL-15R signaling for cancer therapy.
(Crown Copyright © 2024. Published by Elsevier Inc. All rights reserved.)